PMFA
TBPH icon

Plante Moran Financial Advisors’s Theravance Biopharma TBPH Stock Holding History

Plante Moran Financial Advisors’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-20
Closed – – 999
2021
Q4 		$0 Buy
+20
New +$174 ﹤0.01% 1098

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Plante Moran Financial Advisors's TBPH Position: Q1 2022 in Review

Plante Moran Financial Advisors sold out of Theravance Biopharma (TBPH) in Q1 2022, closing a stake of 20 shares.

Plante Moran Financial Advisors first reported a position in TBPH in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 121 funds tracked by Wall St. Rank hold TBPH as of Q1 2022.

  • Plante Moran Financial Advisors reported no remaining Theravance Biopharma position as of Q1 2022 after selling out during the quarter.
  • Plante Moran Financial Advisors sold 20 Theravance Biopharma shares in Q1 2022.
  • Plante Moran Financial Advisors first reported a position in Theravance Biopharma in Q4 2021 and held it in 1 quarter.
  • Plante Moran Financial Advisors's Theravance Biopharma position peaked at $0 in Q4 2021.
  • 121 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2022.

Based on Plante Moran Financial Advisors's 13F filing for Q1 2022, filed 6 May 2022.